Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oxford BioMedica ( (GB:OXB) ) just unveiled an update.
Oxford Biomedica has confirmed that its issued share capital at 31 December 2025 comprised 120,752,962 ordinary shares, with no shares held in treasury, resulting in an equivalent total of 120,752,962 voting rights. The disclosure, made in line with UK financial transparency rules, provides the reference figure shareholders must use to determine whether they need to report holdings or changes in their interest in the company, helping clarify the ownership and governance landscape as the cell and gene therapy CDMO continues to operate as a significant player on the London market.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £735.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score is driven by strong corporate events and positive technical indicators, offset by financial instability and poor valuation metrics. The company’s strategic initiatives and market confidence provide a positive outlook, but financial challenges remain a significant risk.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global, quality- and innovation-led contract development and manufacturing organisation (CDMO) specialising in cell and gene therapies. With 30 years of experience in viral vectors, it partners with leading pharmaceutical and biotechnology companies to provide viral vector development and manufacturing across lentivirus, AAV, adenovirus and other vector types, from early-stage development through to commercialisation. The FTSE 250 and FTSE4Good-listed group operates facilities in the UK, France and the US, offering proprietary manufacturing technologies such as its TetraVecta lentiviral system, dual-plasmid AAV platform, and advanced suspension and perfusion processes.
Average Trading Volume: 254,537
Technical Sentiment Signal: Buy
Current Market Cap: £743.7M
See more insights into OXB stock on TipRanks’ Stock Analysis page.